News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
US FDA to Seek Panel’s Advice on Q-Med AB’s Studies
August 17, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- U.S. Food and Drug Administration staff is seeking a panel's review of Q-Med AB's studies of its Durolane injection for arthritis knee pain, according to documents released ahead of the panel's meeting on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
FDA
Replimune’s melanoma drug would have been rejected again if not for senior CBER official
September 3, 2026
·
2 min read
·
Tristan Manalac
Insights
Breaking borders: Building biotech scale in Benelux
September 3, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Huntington’s disease
UniQure files for FDA, UK approval of first gene therapy for Huntington’s disease
September 2, 2026
·
3 min read
·
Heather McKenzie
Regulatory
Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing
September 2, 2026
·
2 min read
·
Tristan Manalac